CN-122005691-A - Application of banana peel melanin in preparing medicine for treating diabetes

Abstract

The invention discloses application of banana peel melanin in preparing a medicament for treating diabetes, and belongs to the technical field of medicines. The invention separates melanin from banana peel by ethanol extraction, AB-8 macroporous adsorption resin purification, infrared spectrum identification and other technologies, the melanin has obvious inhibition activity on alpha-glucosidase, the half inhibition concentration (IC 50 ) is as low as 3.04 mug/mL, the inhibition effect is superior to that of positive control drug acarbose (IC 50 11.10.10 mug/mL), and the invention provides a high-quality natural raw material for developing novel drugs for treating diabetes. In addition, through enzyme dynamics research, the banana peel melanin can inhibit the activity of alpha-glucosidase through an anti-competition inhibition mechanism, can effectively delay the decomposition and absorption of starch substances in intestinal tracts, reduce postprandial blood glucose peak values, can be used for preparing safe and efficient blood glucose reducing medicines, realizes the high-value utilization of banana peel wastes, and has important economic value and environmental protection significance.

Inventors

• WU CHANGJING
• Zang Pengli
• LI LILI
• MA KESHI
• CUI XIANG
• ZHANG YUNXIA
• LI JIN
• YUAN XINQI
• JIN NA

Assignees

• 周口师范学院
• 河南和济堂生物科技有限公司

Dates

Publication Date

20260512

Application Date

20260320

Claims (6)

1. 1. Application of banana peel melanin in preparing medicine for treating diabetes is provided.
2. 2. The use according to claim 1, wherein the banana peel melanin inhibits alpha-glucosidase activity by an anti-competitive inhibition mechanism.
3. 3. The use according to claim 1, wherein the dosage form of the medicament includes, but is not limited to, one of a tablet, a capsule, a granule, an oral liquid, a suspension or an injection.
4. 4. The use according to claim 1, wherein the medicament further comprises a pharmaceutically acceptable carrier or adjuvant.
5. 5. The use according to claim 4, wherein the method for preparing banana peel melanin comprises the following steps: 1) The preparation of the crude extract comprises mixing banana peel and ethanol according to a feed liquid ratio of 1 (0.5-10) (g/mL), ultrasonic extracting, leaching overnight, rotary steaming to recover ethanol after suction filtration, repeating the extraction and soaking process, and concentrating under reduced pressure at 40-60deg.C until no ethanol exists to obtain crude extract of banana peel; 2) Separating and purifying, namely loading the aqueous suspension of the banana peel crude extract to a pretreated AB-8 macroporous adsorption resin column, adopting ethanol-water gradient elution, collecting 80% and 95% ethanol elution components, merging and concentrating under reduced pressure; 3) Refining, namely dissolving the concentrate with ethanol, collecting insoluble substances, washing with ethanol for a plurality of times, and drying at 40-60 ℃ to obtain the banana peel melanin.
6. 6. The use according to claim 1, wherein during the ethanol-water gradient elution in step 2) water, 20%, 40%, 60%, 80%, 95% ethanol solution is used as eluent in sequence.

Description

Application of banana peel melanin in preparing medicine for treating diabetes Technical Field The invention belongs to the technical field of medicines, and particularly relates to application of banana peel melanin in preparation of a medicine for treating diabetes. Background Diabetes is a global chronic metabolic disease, which is characterized by persistent hyperglycemia, and long-term illness can lead to progressive damage to tissues such as eyes, kidneys, nervous systems, hearts and blood vessels, and seriously threatens human health. Type 2 diabetes is the most common type, and patients often have insulin resistance and progressive loss of islet beta cell function, requiring long-term drug dependence to control blood glucose. The oral medicament for treating diabetes mellitus mainly comprises sulfonylureas, biguanides, thiazolidinediones and the like, but the long-term use is often accompanied with side effects and drug resistance problems. The alpha-glucosidase inhibitor is used as a novel medicament for treating diabetes, reduces postprandial blood glucose peak value by slowing down the decomposition speed of starch by alpha-glucosidase in intestinal tracts, has a unique blood glucose reducing mechanism and becomes an important direction for treating diabetes. However, the existing alpha-glucosidase inhibitor drugs still have certain side effects, and the search for novel, natural and low-toxicity alpha-glucosidase inhibitors has important clinical significance. Bananas are widely consumed fruits worldwide, the outer skin of the bananas accounts for about 30% of the total weight of the fruits, the yield is huge, the utilization rate is extremely low, and the bananas are discarded at will, so that not only is the resource wasted, but also the environmental problem is caused. Researches show that the banana peel is rich in physiological active ingredients such as polysaccharide, polyphenol, organic acid and the like, has potential pharmacological effects such as antioxidation, antibiosis, blood sugar reduction and the like, but the key active ingredients and the action mechanism thereof for reducing the blood sugar in the banana peel are not clear at present, and the development and the utilization of banana peel resources are limited. Disclosure of Invention The present invention aims to solve at least one of the technical problems in the related art to some extent. Therefore, the main purpose of the invention is to provide the application of the banana peel melanin in preparing the medicine for treating diabetes, define the key active ingredients for inhibiting alpha-glucosidase in the banana peel, provide new raw materials and ideas for developing novel medicine for treating diabetes, and realize the high-value utilization of banana peel waste. The invention aims at realizing the following technical scheme: Application of banana peel melanin in preparing medicine for treating diabetes is provided. In certain embodiments, the banana peel melanin inhibits alpha-glucosidase activity by an anti-competitive inhibition mechanism. In certain embodiments, the method for preparing banana peel melanin comprises the following steps: 1) The preparation of the crude extract comprises mixing banana peel and ethanol according to a feed liquid ratio of 1 (0.5-10) (g/mL), ultrasonic extracting, leaching overnight, rotary steaming to recover ethanol after suction filtration, repeating the extraction and soaking process, and concentrating under reduced pressure at 40-60deg.C until no ethanol exists to obtain crude extract of banana peel; 2) Separating and purifying, namely loading the aqueous suspension of the banana peel crude extract to a pretreated AB-8 macroporous adsorption resin column, adopting ethanol-water gradient elution, collecting 80% and 95% ethanol elution components, merging and concentrating under reduced pressure; 3) Refining, namely dissolving the concentrate with ethanol, collecting insoluble substances, washing with ethanol for a plurality of times, and drying at 40-60 ℃ to obtain the banana peel melanin. In certain embodiments, during the ethanol-water gradient elution described in step 2), water, 20%, 40%, 60%, 80%, 95% ethanol solution is used as eluent in sequence. Preferably, the medicament further comprises a pharmaceutically acceptable carrier, such carriers including, but not limited to, diluents, buffers, suspensions, emulsions, granules, encapsulates, excipients, fillers, binders, sprays, transdermal absorbents, wetting agents, disintegrants, absorption enhancers, surfactants, colorants, flavoring agents, or adsorption carriers. The medicament of the invention can be prepared into various dosage forms according to requirements, including but not limited to tablets, solutions, granules, patches, pastes, capsules, aerosols or suppositories. The route of administration of the drug of the present invention is not limited as long as it can exert a desired therapeutic effect or prophylactic